1.9M XNAS Volume
XNAS 18 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.38 per share. | 07 Mar 2025 | 66,723 | 1,203,269 (0%) | 0% | 22.4 | 1,493,261 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2025 | 66,723 | 0 | - | - | Stock Options (Right to Buy) | |
| Kevin T. Conroy | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.06 per share. | 07 Mar 2025 | 48,929 | 1,154,340 (0%) | 0% | 47.1 | 2,302,599 | Common Stock |
| Jacob Orville | EVP, GM, Screening | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 4,725 | 25,001 (0%) | 0% | 0 | Common Stock | |
| Jacob Orville | EVP, GM, Screening | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 4,948 | 14,845 | - | - | Restricted Stock Units | |
| Jacob Orville | EVP, GM, Screening | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 4,725 | 9,450 | - | - | Restricted Stock Units | |
| Jacob Orville | EVP, GM, Screening | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.82 per share. | 28 Feb 2025 | 2,326 | 25,402 (0%) | 0% | 47.8 | 111,229 | Common Stock |
| Jacob Orville | EVP, GM, Screening | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 4,948 | 27,728 (0%) | 0% | 0 | Common Stock | |
| Jacob Orville | EVP, GM, Screening | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.82 per share. | 28 Feb 2025 | 2,221 | 22,780 (0%) | 0% | 47.8 | 106,208 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 18,143 | 1,133,326 (0%) | 0% | 0 | Common Stock | |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 22,167 | 66,504 | - | - | Restricted Stock Units | |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 18,143 | 36,286 | - | - | Restricted Stock Units | |
| Kevin T. Conroy | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.82 per share. | 28 Feb 2025 | 10,419 | 1,136,546 (0%) | 0% | 47.8 | 498,237 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 22,167 | 1,146,965 (0%) | 0% | 0 | Common Stock | |
| Kevin T. Conroy | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.82 per share. | 28 Feb 2025 | 8,528 | 1,124,798 (0%) | 0% | 47.8 | 407,809 | Common Stock |
| Sarah Condella | EVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 3,958 | 84,399 (0%) | 0% | 0 | Common Stock | |
| Sarah Condella | EVP, Human Resources | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.82 per share. | 28 Feb 2025 | 1,777 | 80,441 (0%) | 0% | 47.8 | 84,976 | Common Stock |
| Sarah Condella | EVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 3,780 | 82,218 (0%) | 0% | 0 | Common Stock | |
| Sarah Condella | EVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 3,958 | 11,876 | - | - | Restricted Stock Units | |
| Sarah Condella | EVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 3,780 | 7,560 | - | - | Restricted Stock Units | |
| Sarah Condella | EVP, Human Resources | Gift of securities by or to the insider at price $ 0.00 per share. | 28 Feb 2025 | 1,055 | 81,483 (0%) | 0% | 0 | Common Stock | |
| Sarah Condella | EVP, Human Resources | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.82 per share. | 28 Feb 2025 | 1,861 | 82,538 (0%) | 0% | 47.8 | 88,993 | Common Stock |
| Brian Baranick | EVP, GM, Precision Oncology | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.82 per share. | 28 Feb 2025 | 2,400 | 20,158 (0%) | 0% | 47.8 | 114,768 | Common Stock |
| Brian Baranick | EVP, GM, Precision Oncology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 4,725 | 9,450 | - | - | Restricted Stock Units | |
| Brian Baranick | EVP, GM, Precision Oncology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 4,725 | 22,558 (0%) | 0% | 0 | Common Stock | |
| Brian Baranick | EVP, GM, Precision Oncology | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.82 per share. | 28 Feb 2025 | 2,513 | 22,593 (0%) | 0% | 47.8 | 120,172 | Common Stock |
| Brian Baranick | EVP, GM, Precision Oncology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 4,948 | 14,845 | - | - | Restricted Stock Units | |
| Brian Baranick | EVP, GM, Precision Oncology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 4,948 | 25,106 (0%) | 0% | 0 | Common Stock | |
| James Herriott | SVP, General Counsel & Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 1,890 | 14,853 (0%) | 0% | 0 | Common Stock | |
| James Herriott | SVP, General Counsel & Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 2,375 | 7,125 | - | - | Restricted Stock Units | |
| James Herriott | SVP, General Counsel & Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 1,890 | 3,780 | - | - | Restricted Stock Units | |
| James Herriott | SVP, General Counsel & Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.82 per share. | 28 Feb 2025 | 1,117 | 15,222 (0%) | 0% | 47.8 | 53,415 | Common Stock |
| James Herriott | SVP, General Counsel & Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 2,375 | 16,339 (0%) | 0% | 0 | Common Stock | |
| James Herriott | SVP, General Counsel & Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.82 per share. | 28 Feb 2025 | 889 | 13,964 (0%) | 0% | 47.8 | 42,512 | Common Stock |
| Jacob Orville | EVP, GM, Screening | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 28,779 | 28,779 | - | - | Restricted Stock Units | |
| Jacob Orville | EVP, GM, Screening | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2025 | 3,954 | 3,955 | - | - | Restricted Stock Units | |
| Jacob Orville | EVP, GM, Screening | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2025 | 3,954 | 22,136 (0%) | 0% | 0 | Common Stock | |
| Jacob Orville | EVP, GM, Screening | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.28 per share. | 24 Feb 2025 | 1,859 | 20,277 (0%) | 0% | 51.3 | 95,330 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2025 | 13,180 | 13,181 | - | - | Restricted Stock Units | |
| Kevin T. Conroy | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 111,146 | 111,146 | - | - | Restricted Stock Units | |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2025 | 13,180 | 1,121,378 (0%) | 0% | 0 | Common Stock | |
| Kevin T. Conroy | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.28 per share. | 24 Feb 2025 | 6,195 | 1,115,183 (0%) | 0% | 51.3 | 317,680 | Common Stock |
| Sarah Condella | EVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2025 | 3,954 | 80,297 (0%) | 0% | 0 | Common Stock | |
| Sarah Condella | EVP, Human Resources | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.28 per share. | 24 Feb 2025 | 1,859 | 78,438 (0%) | 0% | 51.3 | 95,330 | Common Stock |
| Sarah Condella | EVP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 23,817 | 23,817 | - | - | Restricted Stock Units | |
| Sarah Condella | EVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2025 | 3,954 | 3,955 | - | - | Restricted Stock Units | |
| Brian Baranick | EVP, GM, Precision Oncology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2025 | 3,954 | 3,955 | - | - | Restricted Stock Units | |
| Brian Baranick | EVP, GM, Precision Oncology | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 28,779 | 28,779 | - | - | Restricted Stock Units | |
| Brian Baranick | EVP, GM, Precision Oncology | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.28 per share. | 24 Feb 2025 | 2,008 | 17,833 (0%) | 0% | 51.3 | 102,970 | Common Stock |
| Brian Baranick | EVP, GM, Precision Oncology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2025 | 3,954 | 19,841 (0%) | 0% | 0 | Common Stock | |
| James Herriott | SVP, General Counsel & Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2025 | 1,647 | 1,648 | - | - | Restricted Stock Units | |
| James Herriott | SVP, General Counsel & Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 13,893 | 13,893 | - | - | Restricted Stock Units | |
| James Herriott | SVP, General Counsel & Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.28 per share. | 24 Feb 2025 | 775 | 12,963 (0%) | 0% | 51.3 | 39,742 | Common Stock |
| James Herriott | SVP, General Counsel & Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2025 | 1,647 | 13,738 (0%) | 0% | 0 | Common Stock | |
| Aaron Bloomer | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 28,779 | 28,779 | - | - | Restricted Stock Units | |
| Jacob Orville | EVP, GM, Screening | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2025 | 2,248 | 0 | - | - | Restricted Stock Units | |
| Jacob Orville | EVP, GM, Screening | Payment of exercise price or tax liability using portion of securities received from the company at price $ 50.48 per share. | 19 Feb 2025 | 2,225 | 18,182 (0%) | 0% | 50.5 | 112,318 | Common Stock |
| Jacob Orville | EVP, GM, Screening | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 4,805 | 20,407 (0%) | 0% | 0 | Common Stock | |
| Jacob Orville | EVP, GM, Screening | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2025 | 2,248 | 16,688 (0%) | 0% | 0 | Common Stock | |
| Jacob Orville | EVP, GM, Screening | Payment of exercise price or tax liability using portion of securities received from the company at price $ 49.63 per share. | 19 Feb 2025 | 1,086 | 15,602 (0%) | 0% | 49.6 | 53,898 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 48,044 | 1,129,338 (0%) | 0% | 0 | Common Stock | |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2025 | 10,374 | 0 | - | - | Restricted Stock Units | |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2025 | 10,374 | 1,084,565 (0%) | 0% | 0 | Common Stock | |
| Kevin T. Conroy | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 49.63 per share. | 19 Feb 2025 | 3,271 | 1,081,294 (0%) | 0% | 49.6 | 162,340 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 50.48 per share. | 19 Feb 2025 | 21,140 | 1,108,198 (0%) | 0% | 50.5 | 1,067,147 | Common Stock |
| D. Scott Coward | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2025 | 2,248 | 0 | - | - | Restricted Stock Units | |
| D. Scott Coward | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2025 | 2,248 | 52,831 (0%) | 0% | 0 | Common Stock | |
| D. Scott Coward | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 49.63 per share. | 19 Feb 2025 | 667 | 52,164 (0%) | 0% | 49.6 | 33,103 | Common Stock |
| Sarah Condella | EVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2025 | 2,248 | 0 | - | - | Restricted Stock Units | |
| Sarah Condella | EVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2025 | 2,248 | 74,859 (0%) | 0% | 0 | Common Stock | |
| Sarah Condella | EVP, Human Resources | Payment of exercise price or tax liability using portion of securities received from the company at price $ 49.63 per share. | 19 Feb 2025 | 1,107 | 73,752 (0%) | 0% | 49.6 | 54,940 | Common Stock |
| Sarah Condella | EVP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 4,805 | 78,557 (0%) | 0% | 0 | Common Stock | |
| Sarah Condella | EVP, Human Resources | Payment of exercise price or tax liability using portion of securities received from the company at price $ 50.48 per share. | 19 Feb 2025 | 2,214 | 76,343 (0%) | 0% | 50.5 | 111,763 | Common Stock |
| Brian Baranick | EVP, GM, Precision Oncology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2025 | 1,729 | 14,487 (0%) | 0% | 0 | Common Stock | |
| Brian Baranick | EVP, GM, Precision Oncology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2025 | 1,729 | 0 | - | - | Restricted Stock Units | |
| Brian Baranick | EVP, GM, Precision Oncology | Payment of exercise price or tax liability using portion of securities received from the company at price $ 50.48 per share. | 19 Feb 2025 | 2,437 | 15,887 (0%) | 0% | 50.5 | 123,020 | Common Stock |
| Brian Baranick | EVP, GM, Precision Oncology | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 4,805 | 18,324 (0%) | 0% | 0 | Common Stock | |
| Brian Baranick | EVP, GM, Precision Oncology | Payment of exercise price or tax liability using portion of securities received from the company at price $ 49.63 per share. | 19 Feb 2025 | 968 | 13,519 (0%) | 0% | 49.6 | 48,042 | Common Stock |
| James Herriott | SVP, General Counsel & Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 49.63 per share. | 19 Feb 2025 | 433 | 10,298 (0%) | 0% | 49.6 | 21,490 | Common Stock |
| James Herriott | SVP, General Counsel & Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2025 | 865 | 0 | - | - | Restricted Stock Units | |
| James Herriott | SVP, General Counsel & Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2025 | 865 | 10,731 (0%) | 0% | 0 | Common Stock | |
| James Herriott | SVP, General Counsel & Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 50.48 per share. | 19 Feb 2025 | 1,531 | 12,091 (0%) | 0% | 50.5 | 77,285 | Common Stock |
| James Herriott | SVP, General Counsel & Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 3,324 | 13,622 (0%) | 0% | 0 | Common Stock | |
| Kimberly J. Popovits | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 6,387 | 6,387 (0%) | 0% | 0 | Common Stock | |
| Kevin T. Conroy | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 51.35 per share. | 13 Nov 2024 | 19,500 | 1,074,191 (0%) | 0% | 51.4 | 1,001,325 | Common Stock |
| Brian Baranick | EVP, GM, Precision Oncology | Sale of securities on an exchange or to another person at price $ 70.00 per share. | 08 Oct 2024 | 929 | 12,758 (0%) | 0% | 70 | 65,030 | Common Stock |
| Brian Baranick | EVP, GM, Precision Oncology | Sale of securities on an exchange or to another person at price $ 70.00 per share. | 18 Sep 2024 | 929 | 13,687 (0%) | 0% | 70 | 65,030 | Common Stock |
| Jacob Orville | EVP, GM, Screening | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2024 | 21,401 | 21,401 | - | - | Restricted Stock Units | |
| Brian Baranick | EVP, GM, Precision Oncology | Payment of exercise price or tax liability using portion of securities received from the company at price $ 55.77 per share. | 05 Aug 2024 | 1,375 | 14,616 (0%) | 0% | 55.8 | 76,684 | Common Stock |
| Brian Baranick | EVP, GM, Precision Oncology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2024 | 2,712 | 15,991 (0%) | 0% | 0 | Common Stock | |
| Brian Baranick | EVP, GM, Precision Oncology | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2024 | 21,401 | 21,401 | - | - | Restricted Stock Units | |
| Brian Baranick | EVP, GM, Precision Oncology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2024 | 2,712 | 0 | - | - | Restricted Stock Units | |
| Katherine S. Zanotti | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 5,444 | 70,073 (0%) | 0% | 0 | Common Stock | |
| Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 5,444 | 20,145 (0%) | 0% | 0 | Common Stock | |
| Daniel Joseph Levangie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 5,444 | 28,419 (0%) | 0% | 0 | Common Stock | |
| James E. Doyle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 5,444 | 55,554 (0%) | 0% | 0 | Common Stock | |
| Scott D. Coward | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 5,444 | 50,088 (0%) | 0% | 0 | Common Stock | |
| Shacey Petrovic | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 5,444 | 15,911 (0%) | 0% | 0 | Common Stock | |
| Kathleen Sebelius | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 6,889 | 31,888 (0%) | 0% | 0 | Common Stock | |
| Michael J. Barber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 7,422 | 7,422 | - | - | Deferred Stock Units | |
| Michael J. Barber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 5,444 | 5,444 (0%) | 0% | 0 | Common Stock | |
| Shacey Petrovic | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 5,939 | 16,406 (0%) | 0% | 0 | Common Stock | |
| Kathleen Sebelius | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 7,672 | 32,671 (0%) | 0% | 0 | Common Stock | |
| Paul Clancy J. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 5,939 | 20,640 (0%) | 0% | 0 | Common Stock | |
| Levangie Daniel Joseph | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 5,939 | 28,914 (0%) | 0% | 0 | Common Stock | |
| Coward D. Scott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 5,939 | 50,583 (0%) | 0% | 0 | Common Stock | |
| Doyle James E. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 5,939 | 56,049 (0%) | 0% | 0 | Common Stock | |
| Zanotti Katherine S. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 5,939 | 70,568 (0%) | 0% | 0 | Common Stock | |
| Barber J. Michael | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 5,939 | 5,939 (0%) | 0% | 0 | Common Stock | |
| Jacob Orville | General Manager, Screening | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2024 | 218 | 14,542 (0%) | 0% | 0 | Common Stock | |
| Jacob Orville | General Manager, Screening | Sale of securities on an exchange or to another person at price $ 60.15 per share. | 30 Apr 2024 | 102 | 14,440 (0%) | 0% | 60.1 | 6,135 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 60.15 per share. | 30 Apr 2024 | 1,155 | 1,156,191 (0%) | 0% | 60.1 | 69,473 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 30.02 per share. | 30 Apr 2024 | 708 | 1,157,346 (0%) | 0% | 30.0 | 21,254 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2024 | 2,489 | 1,156,638 (0%) | 0% | 0 | Common Stock | |
| Everett V. Cunningham | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 30.02 per share. | 30 Apr 2024 | 708 | 47,178 (0%) | 0% | 30.0 | 21,254 | Common Stock |
| Everett V. Cunningham | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2024 | 291 | 46,470 (0%) | 0% | 0 | Common Stock | |
| Everett V. Cunningham | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 60.15 per share. | 30 Apr 2024 | 136 | 47,042 (0%) | 0% | 60.1 | 8,180 | Common Stock |
| Scott D. Coward | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2024 | 218 | 44,711 (0%) | 0% | 0 | Common Stock | |
| Scott D. Coward | Director | Sale of securities on an exchange or to another person at price $ 60.15 per share. | 30 Apr 2024 | 67 | 44,644 (0%) | 0% | 60.1 | 4,030 | Common Stock |
| Jeffrey T. Elliott | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 30.02 per share. | 30 Apr 2024 | 707 | 11,931 (0%) | 0% | 30.0 | 21,224 | Common Stock |
| Jeffrey T. Elliott | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2024 | 291 | 11,224 (0%) | 0% | 0 | Common Stock | |
| Jeffrey T. Elliott | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 60.15 per share. | 30 Apr 2024 | 136 | 11,795 (0%) | 0% | 60.1 | 8,180 | Common Stock |
| Sarah Condella | EVP, Human Resources | Sale of securities on an exchange or to another person at price $ 60.15 per share. | 30 Apr 2024 | 102 | 72,611 (0%) | 0% | 60.1 | 6,135 | Common Stock |
| Sarah Condella | EVP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2024 | 218 | 72,005 (0%) | 0% | 0 | Common Stock | |
| Sarah Condella | EVP, Human Resources | Grant, award, or other acquisition of securities at price $ 30.02 per share. | 30 Apr 2024 | 708 | 72,713 (0%) | 0% | 30.0 | 21,254 | Common Stock |
| Brian Baranick | EVP, GM., Precision Oncology | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2024 | 218 | 13,389 (0%) | 0% | 0 | Common Stock | |
| Brian Baranick | EVP, GM., Precision Oncology | Sale of securities on an exchange or to another person at price $ 60.15 per share. | 30 Apr 2024 | 110 | 13,279 (0%) | 0% | 60.2 | 6,617 | Common Stock |
| James Herriott | SVP, General Counsel & Sec | Sale of securities on an exchange or to another person at price $ 60.17 per share. | 30 Apr 2024 | 30 | 9,866 (0%) | 0% | 60.2 | 1,805 | Common Stock |
| James Herriott | SVP, General Counsel & Sec | Grant, award, or other acquisition of securities at price $ 30.02 per share. | 30 Apr 2024 | 708 | 9,896 (0%) | 0% | 30.0 | 21,254 | Common Stock |
| James Herriott | SVP, General Counsel & Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2024 | 63 | 9,188 (0%) | 0% | 0 | Common Stock | |
| Brian Baranick | EVP, GM., Precision Oncology | Sale of securities on an exchange or to another person at price $ 79.43 per share. | 02 Apr 2024 | 924 | 13,171 (0%) | 0% | 79.4 | 73,393 | Common Stock |
| Sarah Condella | EVP, Human Resources | Sale of securities on an exchange or to another person at price $ 70.00 per share. | 01 Apr 2024 | 2,000 | 71,787 (0%) | 0% | 70 | 140,000 | Common Stock |
| Sarah Condella | EVP, Human Resources | Sale of securities on an exchange or to another person at price $ 70.00 per share. | 28 Mar 2024 | 2,000 | 73,787 (0%) | 0% | 70 | 140,000 | Common Stock |
| Daniel Joseph Levangie | Director | Sale of securities on an exchange or to another person at price $ 57.50 per share. | 01 Mar 2024 | 5,000 | 22,975 (0%) | 0% | 57.5 | 287,500 | Common Stock |
| James E. Doyle | Director | Sale of securities on an exchange or to another person at price $ 57.50 per share. | 01 Mar 2024 | 2,000 | 50,110 (0%) | 0% | 57.5 | 115,000 | Common Stock |
| Jacob Orville | General Manager, Screening | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 4,724 | 16,478 (0%) | 0% | 0 | Common Stock | |
| Jacob Orville | General Manager, Screening | Sale of securities on an exchange or to another person at price $ 59.32 per share. | 29 Feb 2024 | 2,154 | 14,324 (0%) | 0% | 59.3 | 127,775 | Common Stock |
| Jacob Orville | General Manager, Screening | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 4,724 | 14,175 | - | - | Restricted Stock Units | |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 18,143 | 1,307,767 (0%) | 0% | 0 | Common Stock | |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 18,143 | 54,429 | - | - | Restricted Stock Units | |
| Kevin T. Conroy | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 59.32 per share. | 29 Feb 2024 | 8,271 | 1,299,496 (0%) | 0% | 59.3 | 490,636 | Common Stock |
| Everett V. Cunningham | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 59.32 per share. | 29 Feb 2024 | 2,412 | 46,179 (0%) | 0% | 59.3 | 143,080 | Common Stock |
| Everett V. Cunningham | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 5,291 | 48,591 (0%) | 0% | 0 | Common Stock | |
| Everett V. Cunningham | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 5,291 | 15,876 | - | - | Restricted Stock Units | |
| Jeffrey T. Elliott | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 5,291 | 15,876 | - | - | Restricted Stock Units | |
| Jeffrey T. Elliott | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 59.32 per share. | 29 Feb 2024 | 2,412 | 10,933 (0%) | 0% | 59.3 | 143,080 | Common Stock |
| Jeffrey T. Elliott | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 5,291 | 13,345 (0%) | 0% | 0 | Common Stock | |
| Sarah Condella | EVP, Human Resources | Sale of securities on an exchange or to another person at price $ 59.32 per share. | 29 Feb 2024 | 1,724 | 75,787 (0%) | 0% | 59.3 | 102,268 | Common Stock |
| Sarah Condella | EVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 3,779 | 11,340 | - | - | Restricted Stock Units | |
| Sarah Condella | EVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 3,779 | 77,511 (0%) | 0% | 0 | Common Stock | |
| Brian Baranick | Gen. Mgr., Precision Oncology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 4,724 | 14,175 | - | - | Restricted Stock Units | |
| Brian Baranick | Gen. Mgr., Precision Oncology | Sale of securities on an exchange or to another person at price $ 59.32 per share. | 29 Feb 2024 | 2,323 | 14,095 (0%) | 0% | 59.3 | 137,800 | Common Stock |
| Brian Baranick | Gen. Mgr., Precision Oncology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 4,724 | 16,418 (0%) | 0% | 0 | Common Stock | |
| James Herriott | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 1,890 | 9,987 (0%) | 0% | 0 | Common Stock | |
| James Herriott | General Counsel | Sale of securities on an exchange or to another person at price $ 59.32 per share. | 29 Feb 2024 | 862 | 9,125 (0%) | 0% | 59.3 | 51,134 | Common Stock |
| James Herriott | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 1,890 | 5,670 | - | - | Restricted Stock Units | |
| Herriott James | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2024 | 1,648 | 8,881 (0%) | 0% | 0 | Common Stock | |
| T. Elliott Jeffrey | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2024 | 5,701 | 10,764 (0%) | 0% | 0 | Common Stock | |
| Sarah Condella | EVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2024 | 3,954 | 7,909 | - | - | Restricted Stock Units | |
| James Herriott | General Counsel | Sale of securities on an exchange or to another person at price $ 56.89 per share. | 26 Feb 2024 | 784 | 8,097 (0%) | 0% | 56.9 | 44,602 | Common Stock |
| V. Everett Cunningham | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 56.89 per share. | 26 Feb 2024 | 3,648 | 43,300 (0%) | 0% | 56.9 | 207,535 | Common Stock |
| Baranick Brian | Gen. Mgr., Precision Oncology | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 19,793 | 19,793 | - | - | Restricted Stock Units | |
| Condella Sarah | EVP, Human Resources | Sale of securities on an exchange or to another person at price $ 56.89 per share. | 26 Feb 2024 | 1,880 | 73,732 (0%) | 0% | 56.9 | 106,953 | Common Stock |
| Conroy Kevin T. | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 88,671 | 88,671 | - | - | Restricted Stock Units | |
| Baranick Brian | Gen. Mgr., Precision Oncology | Sale of securities on an exchange or to another person at price $ 56.89 per share. | 26 Feb 2024 | 2,027 | 11,694 (0%) | 0% | 56.9 | 115,316 | Common Stock |
| Elliott Jeffrey T. | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2024 | 5,701 | 11,401 | - | - | Restricted Stock Units | |
| Baranick Brian | Gen. Mgr., Precision Oncology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2024 | 3,954 | 13,721 (0%) | 0% | 0 | Common Stock | |
| T. Jeffrey Elliott | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 4,750 | 4,750 | - | - | Restricted Stock Units | |
| Everett Cunningham V. | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2024 | 7,678 | 46,948 (0%) | 0% | 0 | Common Stock | |
| Orville Jacob | General Manager, Screening | Sale of securities on an exchange or to another person at price $ 56.89 per share. | 26 Feb 2024 | 1,879 | 11,754 (0%) | 0% | 56.9 | 106,896 | Common Stock |
| Conroy T. Kevin | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 56.89 per share. | 26 Feb 2024 | 6,263 | 1,289,624 (0%) | 0% | 56.9 | 356,302 | Common Stock |
| James Herriott | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 9,500 | 9,500 | - | - | Restricted Stock Units | |
| T. Conroy Kevin | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2024 | 13,181 | 26,361 | - | - | Restricted Stock Units | |
| Sarah Condella | EVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2024 | 3,954 | 75,612 (0%) | 0% | 0 | Common Stock | |
| Everett Cunningham V. | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2024 | 7,678 | 15,356 | - | - | Restricted Stock Units | |
| Conroy T. Kevin | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2024 | 13,181 | 1,295,887 (0%) | 0% | 0 | Common Stock | |
| Baranick Brian | Gen. Mgr., Precision Oncology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2024 | 3,954 | 7,909 | - | - | Restricted Stock Units | |
| Jacob Orville | General Manager, Screening | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2024 | 3,954 | 13,633 (0%) | 0% | 0 | Common Stock | |
| T. Jeffrey Elliott | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 56.89 per share. | 26 Feb 2024 | 2,710 | 8,054 (0%) | 0% | 56.9 | 154,172 | Common Stock |
| Orville Jacob | General Manager, Screening | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 19,793 | 19,793 | - | - | Restricted Stock Units | |
| Condella Sarah | EVP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 15,834 | 15,834 | - | - | Restricted Stock Units | |
| James Herriott | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2024 | 1,648 | 3,295 | - | - | Restricted Stock Units | |
| Cunningham V. Everett | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 31,668 | 31,668 | - | - | Restricted Stock Units | |
| Jacob Orville | General Manager, Screening | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2024 | 3,954 | 7,909 | - | - | Restricted Stock Units | |
| T. Kevin Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.96 per share. | 23 Feb 2024 | 102,837 | 1,344,266 (0%) | 0% | 14.0 | 1,435,605 | Common Stock |
| T. Kevin Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 102,837 | 0 | - | - | Stock Option (right to buy) | |
| Kevin T. Conroy | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 57.53 per share. | 23 Feb 2024 | 61,560 | 1,282,706 (0%) | 0% | 57.5 | 3,541,547 | Common Stock |
| Condella Sarah | EVP, Human Resources | Sale of securities on an exchange or to another person at price $ 59.72 per share. | 23 Feb 2024 | 1,021 | 71,658 (0%) | 0% | 59.7 | 60,974 | Common Stock |
| Herriott James | General Counsel | Sale of securities on an exchange or to another person at price $ 59.78 per share. | 21 Feb 2024 | 291 | 7,233 (0%) | 0% | 59.8 | 17,396 | Common Stock |
| T. Conroy Kevin | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 59.78 per share. | 21 Feb 2024 | 11,565 | 1,241,429 (0%) | 0% | 59.8 | 691,356 | Common Stock |
| Baranick Brian | Gen. Mgr., Precision Oncology | Sale of securities on an exchange or to another person at price $ 59.78 per share. | 21 Feb 2024 | 1,093 | 9,767 (0%) | 0% | 59.8 | 65,340 | Common Stock |
| Jeffrey T. Elliott | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 2,711 | 6,414 (0%) | 0% | 0 | Common Stock | |
| Orville Jacob | General Manager, Screening | Sale of securities on an exchange or to another person at price $ 59.78 per share. | 21 Feb 2024 | 1,013 | 9,679 (0%) | 0% | 59.8 | 60,557 | Common Stock |
| Everett V. Cunningham | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 2,711 | 40,620 (0%) | 0% | 0 | Common Stock | |
| Herriott James | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 581 | 7,524 (0%) | 0% | 0 | Common Stock | |
| T. Kevin Conroy | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 23,238 | 1,252,994 (0%) | 0% | 0 | Common Stock | |
| T. Jeffrey Elliott | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 59.78 per share. | 21 Feb 2024 | 1,351 | 5,063 (0%) | 0% | 59.8 | 80,763 | Common Stock |
| Coward Scott D. | Director | Sale of securities on an exchange or to another person at price $ 59.78 per share. | 21 Feb 2024 | 663 | 44,493 (0%) | 0% | 59.8 | 39,634 | Common Stock |
| Baranick Brian | Gen. Mgr., Precision Oncology | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 2,034 | 10,860 (0%) | 0% | 0 | Common Stock | |
| Jacob Orville | General Manager, Screening | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 2,034 | 10,692 (0%) | 0% | 0 | Common Stock | |
| Sarah Condella | EVP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 2,034 | 73,692 (0%) | 0% | 0 | Common Stock | |
| Condella Sarah | EVP, Human Resources | Sale of securities on an exchange or to another person at price $ 59.78 per share. | 21 Feb 2024 | 1,013 | 72,679 (0%) | 0% | 59.8 | 60,557 | Common Stock |
| Scott Coward D. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 2,034 | 45,156 (0%) | 0% | 0 | Common Stock | |
| V. Everett Cunningham | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 59.78 per share. | 21 Feb 2024 | 1,350 | 39,270 (0%) | 0% | 59.8 | 80,703 | Common Stock |
| T. Jeffrey Elliott | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 61.50 per share. | 20 Feb 2024 | 1,493 | 3,703 (0%) | 0% | 61.5 | 91,820 | Common Stock |
| Jacob Orville | General Manager, Screening | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2024 | 2,248 | 9,736 (0%) | 0% | 0 | Common Stock | |
| Herriott James | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2024 | 864 | 0 | - | - | Restricted Stock Units | |
| Jacob Orville | General Manager, Screening | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2024 | 2,248 | 0 | - | - | Restricted Stock Units | |
| T. Elliott Jeffrey | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2024 | 3,112 | 0 | - | - | Restricted Stock Units | |
| Condella Sarah | EVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2024 | 2,248 | 0 | - | - | Restricted Stock Units | |
| Sarah Condella | EVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2024 | 2,248 | 72,737 (0%) | 0% | 0 | Common Stock | |
| Kevin Conroy T. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2024 | 10,374 | 1,234,731 (0%) | 0% | 0 | Common Stock | |
| Brian Baranick | Gen. Mgr., Precision Oncology | Sale of securities on an exchange or to another person at price $ 61.50 per share. | 20 Feb 2024 | 895 | 8,826 (0%) | 0% | 61.5 | 55,043 | Common Stock |
| Baranick Brian | Gen. Mgr., Precision Oncology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2024 | 1,729 | 9,721 (0%) | 0% | 0 | Common Stock | |
| Condella Sarah | EVP, Human Resources | Sale of securities on an exchange or to another person at price $ 61.50 per share. | 20 Feb 2024 | 1,079 | 71,658 (0%) | 0% | 61.5 | 66,359 | Common Stock |
| Coward D. Scott | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2024 | 2,248 | 43,828 (0%) | 0% | 0 | Common Stock | |
| James Herriott | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2024 | 864 | 7,358 (0%) | 0% | 0 | Common Stock | |
| Orville Jacob | General Manager, Screening | Sale of securities on an exchange or to another person at price $ 61.50 per share. | 20 Feb 2024 | 1,078 | 8,658 (0%) | 0% | 61.5 | 66,297 | Common Stock |
| Baranick Brian | Gen. Mgr., Precision Oncology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2024 | 1,729 | 0 | - | - | Restricted Stock Units | |
| Herriott James | General Counsel | Sale of securities on an exchange or to another person at price $ 61.50 per share. | 20 Feb 2024 | 415 | 6,943 (0%) | 0% | 61.5 | 25,523 | Common Stock |
| D. Scott Coward | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2024 | 2,248 | 0 | - | - | Restricted Stock Units | |
| Conroy Kevin T. | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 61.50 per share. | 20 Feb 2024 | 4,975 | 1,229,756 (0%) | 0% | 61.5 | 305,963 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2024 | 10,374 | 0 | - | - | Restricted Stock Units | |
| T. Jeffrey Elliott | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2024 | 3,112 | 5,196 (0%) | 0% | 0 | Common Stock | |
| Coward D. Scott | Director | Sale of securities on an exchange or to another person at price $ 61.50 per share. | 20 Feb 2024 | 706 | 43,122 (0%) | 0% | 61.5 | 43,419 | Common Stock |
| Elliott T. Jeffrey | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 61.43 per share. | 14 Feb 2024 | 1,888 | 2,084 (0%) | 0% | 61.4 | 115,980 | Common Stock |
| T. Kevin Conroy | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 30.02 per share. | 14 Feb 2024 | 709 | 1,208,015 (0%) | 0% | 30.0 | 21,284 | Common Stock |
| Jacob Orville | General Manager, Screening | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 2,031 | 8,454 (0%) | 0% | 0 | Common Stock | |
| Scott D. Coward | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 3,972 | 0 | - | - | Restricted Stock Units | |
| Kevin Conroy T. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 31,133 | 1,239,148 (0%) | 0% | 0 | Common Stock | |
| James Herriott | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 883 | 0 | - | - | Restricted Stock Units | |
| Coward Scott D. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 3,972 | 42,956 (0%) | 0% | 0 | Common Stock | |
| Coward D. Scott | Director | Sale of securities on an exchange or to another person at price $ 61.43 per share. | 14 Feb 2024 | 1,376 | 41,580 (0%) | 0% | 61.4 | 84,528 | Common Stock |
| T. Kevin Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 31,133 | 0 | - | - | Restricted Stock Units | |
| T. Jeffrey Elliott | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 3,972 | 3,972 (0%) | 0% | 0 | Common Stock | |
| Elliott T. Jeffrey | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 3,972 | 0 | - | - | Restricted Stock Units | |
| Condella Sarah | EVP, Human Resources | Sale of securities on an exchange or to another person at price $ 61.43 per share. | 14 Feb 2024 | 965 | 70,489 (0%) | 0% | 61.4 | 59,280 | Common Stock |
| Orville Jacob | General Manager, Screening | Sale of securities on an exchange or to another person at price $ 61.43 per share. | 14 Feb 2024 | 966 | 7,488 (0%) | 0% | 61.4 | 59,341 | Common Stock |
| James Herriott | General Counsel | Grant, award, or other acquisition of securities at price $ 30.01 per share. | 14 Feb 2024 | 68 | 6,032 (0%) | 0% | 30.0 | 2,041 | Common Stock |
| Sarah Condella | EVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 2,031 | 71,454 (0%) | 0% | 0 | Common Stock | |
| James Herriott | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 883 | 6,915 (0%) | 0% | 0 | Common Stock | |
| Sarah Condella | EVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 2,031 | 0 | - | - | Restricted Stock Units | |
| Jacob Orville | General Manager, Screening | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 2,031 | 0 | - | - | Restricted Stock Units | |
| James Herriott | General Counsel | Sale of securities on an exchange or to another person at price $ 61.43 per share. | 14 Feb 2024 | 421 | 6,494 (0%) | 0% | 61.4 | 25,862 | Common Stock |
| Conroy T. Kevin | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 61.43 per share. | 14 Feb 2024 | 14,791 | 1,224,357 (0%) | 0% | 61.4 | 908,611 | Common Stock |
| Condella Sarah | EVP, Human Resources | Sale of securities on an exchange or to another person at price $ 73.50 per share. | 02 Jan 2024 | 2,000 | 69,423 (0%) | 0% | 73.5 | 147,000 | Common Stock |
| Baranick Brian | Gen. Mgr., Precision Oncology | Sale of securities on an exchange or to another person at price $ 73.50 per share. | 02 Jan 2024 | 879 | 7,992 (0%) | 0% | 73.5 | 64,607 | Common Stock |
| Condella Sarah | EVP, Human Resources | Sale of securities on an exchange or to another person at price $ 70.00 per share. | 14 Dec 2023 | 2,000 | 71,423 (0%) | 0% | 70 | 140,000 | Common Stock |
| Jeffrey T. Elliott | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 82.92 per share. | 21 Aug 2023 | 30,210 | 0 (0%) | 0% | 82.9 | 2,505,013 | Common Stock |
| Jeffrey T. Elliott | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 47.41 per share. | 21 Aug 2023 | 260 | 29,501 (0%) | 0% | 47.4 | 12,327 | Common Stock |
| Jeffrey T. Elliott | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 30.02 per share. | 21 Aug 2023 | 709 | 30,210 (0%) | 0% | 30.0 | 21,284 | Common Stock |
| Brian Baranick | Gen. Mgr., Precision Oncology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Aug 2023 | 2,712 | 10,221 (0%) | 0% | 0 | Common Stock | |
| Brian Baranick | Gen. Mgr., Precision Oncology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Aug 2023 | 2,712 | 2,712 | - | - | Restricted Stock Units | |
| Brian Baranick | Gen. Mgr., Precision Oncology | Sale of securities on an exchange or to another person at price $ 85.04 per share. | 04 Aug 2023 | 1,350 | 8,871 (0%) | 0% | 85.0 | 114,804 | Common Stock |
| James E. Doyle | Director | Sale of securities on an exchange or to another person at price $ 97.42 per share. | 27 Jul 2023 | 2,000 | 52,110 (0%) | 0% | 97.4 | 194,840 | Common Stock |
| James Herriott | General Counsel | Sale of securities on an exchange or to another person at price $ 100.00 per share. | 19 Jul 2023 | 1,300 | 5,964 (0%) | 0% | 100 | 130,000 | Common Stock |
| Katherine S. Zanotti | Director | Sale of securities on an exchange or to another person at price $ 90.51 per share. | 08 Jun 2023 | 3,027 | 64,629 (0%) | 0% | 90.5 | 273,974 | Common Stock |
| Katherine S. Zanotti | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 3,599 | 67,656 (0%) | 0% | 0 | Common Stock | |
| Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 3,599 | 14,701 (0%) | 0% | 0 | Common Stock | |
| Freda C. Lewis-Hall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 3,599 | 19,688 (0%) | 0% | 0 | Common Stock | |
| Daniel Joseph Levangie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 4,678 | 27,975 (0%) | 0% | 0 | Common Stock | |
| James E. Doyle | Director | Sale of securities on an exchange or to another person at price $ 90.51 per share. | 08 Jun 2023 | 1,402 | 54,110 (0%) | 0% | 90.5 | 126,895 | Common Stock |
| James E. Doyle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 3,599 | 55,512 (0%) | 0% | 0 | Common Stock | |
| Scott D. Coward | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 6,209 | 38,984 (0%) | 0% | 0 | Common Stock | |
| Shacey Petrovic | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 3,599 | 17,562 (0%) | 0% | 0 | Common Stock | |
| Kathleen Sebelius | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 3,599 | 24,999 (0%) | 0% | 0 | Common Stock | |
| Pierre Jacquet | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 4,580 | 23,576 (0%) | 0% | 0 | Common Stock | |
| James Herriott | General Counsel | Sale of securities on an exchange or to another person at price $ 90.00 per share. | 08 Jun 2023 | 1,300 | 7,264 (0%) | 0% | 90 | 117,000 | Common Stock |
| James E. Doyle | Director | Sale of securities on an exchange or to another person at price $ 80.62 per share. | 26 May 2023 | 2,000 | 51,913 (0%) | 0% | 80.6 | 161,240 | Common Stock |
| Sarah Condella | EVP, Human Resources | Sale of securities on an exchange or to another person at price $ 80.00 per share. | 10 May 2023 | 6,087 | 80,314 (0%) | 0% | 80 | 486,960 | Common Stock |
| James Herriott | General Counsel | Sale of securities on an exchange or to another person at price $ 79.85 per share. | 10 May 2023 | 1,300 | 8,564 (0%) | 0% | 79.9 | 103,805 | Common Stock |
| James Herriott | General Counsel | Grant, award, or other acquisition of securities at price $ 30.02 per share. | 10 May 2023 | 640 | 9,864 (0%) | 0% | 30.0 | 19,213 | Common Stock |
| Sarah Condella | EVP, Human Resources | Grant, award, or other acquisition of securities at price $ 30.02 per share. | 01 May 2023 | 709 | 87,401 (0%) | 0% | 30.0 | 21,284 | Common Stock |
| Sarah Condella | EVP, Human Resources | Sale of securities on an exchange or to another person at price $ 63.78 per share. | 01 May 2023 | 1,000 | 86,401 (0%) | 0% | 63.8 | 63,780 | Common Stock |
| Sarah Condella | EVP, Human Resources | Sale of securities on an exchange or to another person at price $ 67.19 per share. | 03 Apr 2023 | 1,000 | 86,692 (0%) | 0% | 67.2 | 67,190 | Common Stock |
| Everett V. Cunningham | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 62.01 per share. | 01 Mar 2023 | 3,628 | 22,703 (0%) | 0% | 62.0 | 224,972 | Common Stock |
| Sarah Condella | EVP, Human Resources | Sale of securities on an exchange or to another person at price $ 62.00 per share. | 01 Mar 2023 | 1,000 | 87,692 (0%) | 0% | 62 | 62,000 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2023 | 13,180 | 39,541 | - | - | Restricted Stock Units | |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2023 | 9,312 | 0 | - | - | Restricted Stock Units | |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2023 | 13,180 | 1,208,410 (0%) | 0% | 0 | Common Stock | |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2023 | 9,312 | 1,217,722 (0%) | 0% | 0 | Common Stock | |
| Kevin T. Conroy | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 61.12 per share. | 27 Feb 2023 | 10,416 | 1,207,306 (0%) | 0% | 61.1 | 636,626 | Common Stock |
| Everett V. Cunningham | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2023 | 7,677 | 26,331 (0%) | 0% | 0 | Common Stock | |
| Everett V. Cunningham | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2023 | 7,677 | 23,034 | - | - | Restricted Stock Units | |
| Scott D. Coward | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2023 | 3,263 | 0 | - | - | Restricted Stock Units | |
| Scott D. Coward | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2023 | 5,931 | 33,665 (0%) | 0% | 0 | Common Stock | |
| Scott D. Coward | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2023 | 3,263 | 36,928 (0%) | 0% | 0 | Common Stock | |
| Scott D. Coward | Director | Sale of securities on an exchange or to another person at price $ 61.12 per share. | 27 Feb 2023 | 4,153 | 32,775 (0%) | 0% | 61.1 | 253,831 | Common Stock |
| Scott D. Coward | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2023 | 5,931 | 0 | - | - | Restricted Stock Units | |
| Jeffrey T. Elliott | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2023 | 3,437 | 0 | - | - | Restricted Stock Units | |
| Jeffrey T. Elliott | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2023 | 5,700 | 17,102 | - | - | Restricted Stock Units | |
| Jeffrey T. Elliott | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 61.12 per share. | 27 Feb 2023 | 4,233 | 29,241 (0%) | 0% | 61.1 | 258,721 | Common Stock |
| Jeffrey T. Elliott | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2023 | 3,437 | 33,474 (0%) | 0% | 0 | Common Stock | |
| Jeffrey T. Elliott | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2023 | 5,700 | 30,037 (0%) | 0% | 0 | Common Stock | |
| Sarah Condella | EVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2023 | 3,954 | 11,863 | - | - | Restricted Stock Units | |
| Sarah Condella | EVP, Human Resources | Sale of securities on an exchange or to another person at price $ 61.12 per share. | 27 Feb 2023 | 2,924 | 88,692 (0%) | 0% | 61.1 | 178,715 | Common Stock |
| Sarah Condella | EVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2023 | 2,357 | 91,616 (0%) | 0% | 0 | Common Stock | |
| Sarah Condella | EVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2023 | 3,954 | 89,259 (0%) | 0% | 0 | Common Stock | |
| Sarah Condella | EVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2023 | 2,357 | 0 | - | - | Restricted Stock Units | |
| Brian Baranick | Gen. Mgr., Precision Oncology | Sale of securities on an exchange or to another person at price $ 61.12 per share. | 27 Feb 2023 | 1,932 | 7,509 (0%) | 0% | 61.1 | 118,084 | Common Stock |
| Brian Baranick | Gen. Mgr., Precision Oncology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2023 | 3,954 | 9,441 (0%) | 0% | 0 | Common Stock | |
| Brian Baranick | Gen. Mgr., Precision Oncology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2023 | 3,954 | 11,863 | - | - | Restricted Stock Units | |
| James Herriott | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2023 | 240 | 11,449 (0%) | 0% | 0 | Common Stock | |
| James Herriott | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2023 | 1,647 | 11,209 (0%) | 0% | 0 | Common Stock | |
| James Herriott | General Counsel | Sale of securities on an exchange or to another person at price $ 59.98 per share. | 27 Feb 2023 | 1,350 | 10,099 (0%) | 0% | 60.0 | 80,973 | Common Stock |
| James Herriott | General Counsel | Sale of securities on an exchange or to another person at price $ 61.12 per share. | 27 Feb 2023 | 875 | 9,224 (0%) | 0% | 61.1 | 53,480 | Common Stock |
| James Herriott | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2023 | 1,647 | 4,943 | - | - | Restricted Stock Units | |
| James Herriott | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2023 | 240 | 0 | - | - | Restricted Stock Units | |
| Kevin T. Conroy | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 72,572 | 72,572 | - | - | Restricted Stock Units | |
| Everett V. Cunningham | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 21,167 | 21,167 | - | - | Restricted Stock Units | |
| Jeffrey T. Elliott | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 21,167 | 21,167 | - | - | Restricted Stock Units | |
| Sarah Condella | EVP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 15,119 | 15,119 | - | - | Restricted Stock Units | |
| Brian Baranick | Gen. Mgr., Precision Oncology | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 18,899 | 18,899 | - | - | Restricted Stock Units | |
| James Herriott | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 7,560 | 7,560 | - | - | Restricted Stock Units | |
| Kevin T. Conroy | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 62.72 per share. | 21 Feb 2023 | 4,764 | 1,195,230 (0%) | 0% | 62.7 | 298,798 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2023 | 10,374 | 20,747 | - | - | Restricted Stock Units | |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2023 | 10,374 | 1,199,994 (0%) | 0% | 0 | Common Stock | |
| Scott D. Coward | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2023 | 2,248 | 28,741 (0%) | 0% | 0 | Common Stock | |
| Scott D. Coward | Director | Sale of securities on an exchange or to another person at price $ 62.72 per share. | 21 Feb 2023 | 1,007 | 27,734 (0%) | 0% | 62.7 | 63,159 | Common Stock |
| Scott D. Coward | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2023 | 2,248 | 4,495 | - | - | Restricted Stock Units | |
| Jeffrey T. Elliott | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 62.72 per share. | 21 Feb 2023 | 1,430 | 24,337 (0%) | 0% | 62.7 | 89,690 | Common Stock |
| Jeffrey T. Elliott | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2023 | 3,112 | 6,225 | - | - | Restricted Stock Units | |
| Jeffrey T. Elliott | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2023 | 3,112 | 25,767 (0%) | 0% | 0 | Common Stock | |
| Sarah Condella | EVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2023 | 2,248 | 86,338 (0%) | 0% | 0 | Common Stock | |
| Sarah Condella | EVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2023 | 2,248 | 4,495 | - | - | Restricted Stock Units | |
| Sarah Condella | EVP, Human Resources | Sale of securities on an exchange or to another person at price $ 62.72 per share. | 21 Feb 2023 | 1,033 | 85,305 (0%) | 0% | 62.7 | 64,790 | Common Stock |
| Brian Baranick | Gen. Mgr., Precision Oncology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2023 | 1,729 | 6,325 (0%) | 0% | 0 | Common Stock | |
| Brian Baranick | Gen. Mgr., Precision Oncology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2023 | 1,729 | 3,458 | - | - | Restricted Stock Units | |
| Brian Baranick | Gen. Mgr., Precision Oncology | Sale of securities on an exchange or to another person at price $ 62.72 per share. | 21 Feb 2023 | 838 | 5,487 (0%) | 0% | 62.7 | 52,559 | Common Stock |
| James Herriott | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2023 | 865 | 1,728 | - | - | Restricted Stock Units | |
| James Herriott | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2023 | 865 | 9,960 (0%) | 0% | 0 | Common Stock | |
| James Herriott | General Counsel | Sale of securities on an exchange or to another person at price $ 62.72 per share. | 21 Feb 2023 | 398 | 9,562 (0%) | 0% | 62.7 | 24,963 | Common Stock |
| Sarah Condella | EVP, Human Resources | Sale of securities on an exchange or to another person at price $ 63.91 per share. | 16 Feb 2023 | 1,076 | 84,090 (0%) | 0% | 63.9 | 68,767 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 31,132 | 31,132 | - | - | Restricted Stock Units | |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 31,132 | 1,204,237 (0%) | 0% | 0 | Common Stock | |
| Kevin T. Conroy | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 65.59 per share. | 14 Feb 2023 | 14,617 | 1,189,620 (0%) | 0% | 65.6 | 958,729 | Common Stock |
| Scott D. Coward | Director | Sale of securities on an exchange or to another person at price $ 65.59 per share. | 14 Feb 2023 | 1,821 | 26,493 (0%) | 0% | 65.6 | 119,439 | Common Stock |
| Scott D. Coward | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 3,972 | 3,972 | - | - | Restricted Stock Units | |
| Scott D. Coward | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 3,972 | 28,314 (0%) | 0% | 0 | Common Stock | |
| Jeffrey T. Elliott | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 65.59 per share. | 14 Feb 2023 | 1,866 | 22,655 (0%) | 0% | 65.6 | 122,391 | Common Stock |
| Jeffrey T. Elliott | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 3,972 | 24,521 (0%) | 0% | 0 | Common Stock | |
| Jeffrey T. Elliott | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 3,972 | 3,972 | - | - | Restricted Stock Units | |
| Sarah Condella | EVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 2,030 | 86,120 (0%) | 0% | 0 | Common Stock | |
| Sarah Condella | EVP, Human Resources | Sale of securities on an exchange or to another person at price $ 65.59 per share. | 14 Feb 2023 | 954 | 85,166 (0%) | 0% | 65.6 | 62,573 | Common Stock |
| Sarah Condella | EVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 2,030 | 2,031 | - | - | Restricted Stock Units | |
| James Herriott | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 883 | 9,495 (0%) | 0% | 0 | Common Stock | |
| James Herriott | General Counsel | Sale of securities on an exchange or to another person at price $ 65.59 per share. | 14 Feb 2023 | 400 | 9,095 (0%) | 0% | 65.6 | 26,236 | Common Stock |
| James Herriott | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 883 | 883 | - | - | Restricted Stock Units | |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 9,705 | 0 | - | - | Performance Stock Units | |
| Kevin T. Conroy | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 64.55 per share. | 10 Feb 2023 | 4,527 | 1,173,105 (0%) | 0% | 64.6 | 292,218 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 9,705 | 1,177,632 (0%) | 0% | 0 | Common Stock | |
| Jeffrey T. Elliott | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 64.55 per share. | 10 Feb 2023 | 1,158 | 20,549 (0%) | 0% | 64.6 | 74,749 | Common Stock |
| Jeffrey T. Elliott | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 2,579 | 21,707 (0%) | 0% | 0 | Common Stock | |
| Jeffrey T. Elliott | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 2,579 | 0 | - | - | Performance Stock Units | |
| Sarah Condella | EVP, Human Resources | Sale of securities on an exchange or to another person at price $ 67.93 per share. | 01 Feb 2023 | 1,000 | 84,090 (0%) | 0% | 67.9 | 67,930 | Common Stock |
| James E. Doyle | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.52 per share. | 13 Jan 2023 | 5,477 | 53,913 (0%) | 0% | 16.5 | 90,480 | Common Stock |
| James E. Doyle | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 5,477 | 0 | - | - | Stock Option (right to buy) | |
| Sarah Condella | EVP, Human Resources | Grant, award, or other acquisition of securities at price $ 47.41 per share. | 09 Jan 2023 | 328 | 86,090 (0%) | 0% | 47.4 | 15,550 | Common Stock |
| Sarah Condella | EVP, Human Resources | Sale of securities on an exchange or to another person at price $ 60.00 per share. | 09 Jan 2023 | 1,000 | 85,090 (0%) | 0% | 60 | 60,000 | Common Stock |
| Scott D. Coward | Director | Grant, award, or other acquisition of securities at price $ 47.41 per share. | 03 Jan 2023 | 328 | 16,562 (0%) | 0% | 47.4 | 15,550 | Common Stock |
| Scott D. Coward | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 7,780 | 24,342 (0%) | 0% | 0 | Common Stock | |
| Everett V. Cunningham | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Oct 2022 | 20,003 | 20,523 (0%) | 0% | 0 | Common Stock | |
| Everett V. Cunningham | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Oct 2022 | 15,003 | 15,002 | - | - | Restricted Stock Unit | |
| Everett V. Cunningham | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Oct 2022 | 20,003 | 40,007 | - | - | Restricted Stock Unit | |
| Everett V. Cunningham | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 31.37 per share. | 11 Oct 2022 | 16,872 | 18,654 (0%) | 0% | 31.4 | 529,275 | Common Stock |
| Everett V. Cunningham | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Oct 2022 | 15,003 | 35,526 (0%) | 0% | 0 | Common Stock | |
| Everett V. Cunningham | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 47.41 per share. | 11 Oct 2022 | 520 | 520 (0%) | 0% | 47.4 | 24,653 | Common Stock |
| Brian Baranick | Gen. Mgr., Precision Oncology | Sale of securities on an exchange or to another person at price $ 47.12 per share. | 04 Aug 2022 | 984 | 4,596 (0%) | 0% | 47.1 | 46,366 | Common Stock |
| Brian Baranick | Gen. Mgr., Precision Oncology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Aug 2022 | 2,712 | 5,424 | - | - | Restricted Stock Units | |
| Brian Baranick | Gen. Mgr., Precision Oncology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Aug 2022 | 2,712 | 5,580 (0%) | 0% | 0 | Common Stock | |
| Katherine S. Zanotti | Director | Sale of securities on an exchange or to another person at price $ 45.14 per share. | 26 Jul 2022 | 4,608 | 60,318 (0%) | 0% | 45.1 | 208,005 | Common Stock |
| Katherine S. Zanotti | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jul 2022 | 4,608 | 0 | - | - | Stock Option (right to buy) | |
| Katherine S. Zanotti | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.18 per share. | 26 Jul 2022 | 4,608 | 64,926 (0%) | 0% | 10.2 | 46,909 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 40.71 per share. | 01 Jul 2022 | 7 | 1,167,927 (0%) | 0% | 40.7 | 285 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 47.41 per share. | 01 Jul 2022 | 328 | 1,167,934 (0%) | 0% | 47.4 | 15,550 | Common Stock |
| Katherine S. Zanotti | Director | Sale of securities on an exchange or to another person at price $ 40.13 per share. | 30 Jun 2022 | 1,086 | 60,318 (0%) | 0% | 40.1 | 43,581 | Common Stock |
| Katherine S. Zanotti | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 5,606 | 61,404 (0%) | 0% | 0 | Common Stock | |
| Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 5,606 | 11,102 (0%) | 0% | 0 | Common Stock | |
| Freda C. Lewis-Hall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 5,606 | 16,089 (0%) | 0% | 0 | Common Stock | |
| Daniel Joseph Levangie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 5,606 | 23,297 (0%) | 0% | 0 | Common Stock | |
| James E. Doyle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 5,606 | 48,436 (0%) | 0% | 0 | Common Stock | |
| Shacey Petrovic | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 5,606 | 13,963 (0%) | 0% | 0 | Common Stock | |
| Kathleen Sebelius | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 7,523 | 21,400 (0%) | 0% | 0 | Common Stock | |
| Pierre Jacquet | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 7,243 | 18,996 (0%) | 0% | 0 | Common Stock | |
| James E. Doyle | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2022 | 3,000 | 5,477 | - | - | Stock Option (right to buy) | |
| James E. Doyle | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.52 per share. | 07 Jun 2022 | 3,000 | 42,830 (0%) | 0% | 16.5 | 49,560 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.70 per share. | 17 Mar 2022 | 229,757 | 1,160,741 (0%) | 0% | 5.7 | 1,309,615 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Mar 2022 | 2,253 | 66,047 | - | - | Stock Option (right to buy) | |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Mar 2022 | 4,612 | 235,388 | - | - | Stock Option (right to buy) | |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Mar 2022 | 229,757 | 0 | - | - | Stock Option (right to buy) | |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 44.37 per share. | 17 Mar 2022 | 2,253 | 1,167,606 (0%) | 0% | 44.4 | 99,966 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.68 per share. | 17 Mar 2022 | 4,612 | 1,165,353 (0%) | 0% | 21.7 | 99,988 | Common Stock |
| James E. Doyle | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.52 per share. | 17 Mar 2022 | 10,000 | 39,830 (0%) | 0% | 16.5 | 165,200 | Common Stock |
| James E. Doyle | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Mar 2022 | 10,000 | 8,477 | - | - | Stock Option (right to buy) | |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 20,575 | 935,971 (0%) | 0% | 0 | Common Stock | |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 9,312 | 945,283 (0%) | 0% | 0 | Common Stock | |
| Kevin T. Conroy | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 76.69 per share. | 28 Feb 2022 | 14,299 | 930,984 (0%) | 0% | 76.7 | 1,096,590 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 20,575 | 0 | - | - | Restricted Stock Units | |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 9,312 | 9,312 | - | - | Restricted Stock Units | |
| Scott D. Coward | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 5,025 | 16,883 (0%) | 0% | 0 | Common Stock | |
| Scott D. Coward | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 3,263 | 20,146 (0%) | 0% | 0 | Common Stock | |
| Scott D. Coward | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 76.69 per share. | 28 Feb 2022 | 3,912 | 16,234 (0%) | 0% | 76.7 | 300,011 | Common Stock |
| Scott D. Coward | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 5,025 | 0 | - | - | Restricted Stock Units | |
| Scott D. Coward | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 3,263 | 3,262 | - | - | Restricted Stock Units | |
| Jeffrey T. Elliott | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 3,437 | 3,436 | - | - | Restricted Stock Units | |
| Jeffrey T. Elliott | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 5,025 | 0 | - | - | Restricted Stock Units | |
| Jeffrey T. Elliott | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 5,025 | 19,741 (0%) | 0% | 0 | Common Stock | |
| Jeffrey T. Elliott | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 3,437 | 23,178 (0%) | 0% | 0 | Common Stock | |
| Jeffrey T. Elliott | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 76.69 per share. | 28 Feb 2022 | 4,050 | 19,128 (0%) | 0% | 76.7 | 310,595 | Common Stock |
| Sarah Condella | EVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 3,525 | 86,222 (0%) | 0% | 0 | Common Stock | |
| Sarah Condella | EVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 3,525 | 0 | - | - | Restricted Stock Units | |
| Sarah Condella | EVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 2,356 | 2,356 | - | - | Restricted Stock Units | |
| Sarah Condella | EVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 2,356 | 88,578 (0%) | 0% | 0 | Common Stock | |
| Sarah Condella | EVP, Human Resources | Sale of securities on an exchange or to another person at price $ 76.69 per share. | 28 Feb 2022 | 2,816 | 85,762 (0%) | 0% | 76.7 | 215,959 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 52,722 | 52,722 | - | - | Restricted Stock Units | |
| Everett V. Cunningham | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 30,711 | 30,711 | - | - | Restricted Stock Units | |
| Scott D. Coward | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 5,931 | 5,931 | - | - | Restricted Stock Units | |
| Jeffrey T. Elliott | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 22,802 | 22,802 | - | - | Restricted Stock Units | |
| Sarah Condella | SVP, Human Resources | Sale of securities on an exchange or to another person at price $ 75.15 per share. | 25 Feb 2022 | 680 | 82,697 (0%) | 0% | 75.2 | 51,102 | Common Stock |
| Sarah Condella | SVP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 15,817 | 15,817 | - | - | Restricted Stock Units | |
| Sarah Condella | SVP, Human Resources | Sale of securities on an exchange or to another person at price $ 74.05 per share. | 25 Feb 2022 | 4,800 | 83,377 (0%) | 0% | 74.1 | 355,440 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2022 | 10,373 | 31,122 | - | - | Restricted Stock Units | |
| Kevin T. Conroy | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 69.05 per share. | 22 Feb 2022 | 5,188 | 883,879 (0%) | 0% | 69.0 | 358,231 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2022 | 10,373 | 889,067 (0%) | 0% | 0 | Common Stock | |
| Scott D. Coward | Chief Administrative Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2022 | 2,247 | 6,035 (0%) | 0% | 0 | Common Stock | |
| Scott D. Coward | Chief Administrative Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2022 | 2,247 | 6,744 | - | - | Restricted Stock Units | |
| Scott D. Coward | Chief Administrative Officer | Sale of securities on an exchange or to another person at price $ 69.05 per share. | 22 Feb 2022 | 1,109 | 4,926 (0%) | 0% | 69.0 | 76,576 | Common Stock |
| Jeffrey T. Elliott | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2022 | 3,112 | 9,337 | - | - | Restricted Stock Units | |
| Jeffrey T. Elliott | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2022 | 3,112 | 9,423 (0%) | 0% | 0 | Common Stock | |
| Jeffrey T. Elliott | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 69.05 per share. | 22 Feb 2022 | 1,557 | 7,866 (0%) | 0% | 69.1 | 107,511 | Common Stock |
| Sarah Condella | SVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2022 | 2,247 | 83,821 (0%) | 0% | 0 | Common Stock | |
| Sarah Condella | SVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2022 | 2,247 | 6,744 | - | - | Restricted Stock Units | |
| Sarah Condella | SVP, Human Resources | Sale of securities on an exchange or to another person at price $ 69.05 per share. | 22 Feb 2022 | 1,124 | 82,697 (0%) | 0% | 69.0 | 77,612 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 31,133 | 62,265 | - | - | Restricted Stock Units | |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 96,758 | 0 | - | - | Stock Option (right to buy) | |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 94,425 | 0 | - | - | Stock Option (right to buy) | |
| Kevin T. Conroy | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 79.55 per share. | 14 Feb 2022 | 14,409 | 878,694 (0%) | 0% | 79.6 | 1,146,236 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 78.33 per share. | 14 Feb 2022 | 31,133 | 893,103 (0%) | 0% | 78.3 | 2,438,648 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.82 per share. | 14 Feb 2022 | 96,758 | 861,970 (0%) | 0% | 10.8 | 1,046,922 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.07 per share. | 14 Feb 2022 | 94,425 | 765,212 (0%) | 0% | 9.1 | 856,435 | Common Stock |
| Scott D. Coward | Chief Administrative Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 3,972 | 7,944 | - | - | Restricted Stock Units | |
| Scott D. Coward | Chief Administrative Officer | Sale of securities on an exchange or to another person at price $ 79.55 per share. | 14 Feb 2022 | 1,813 | 3,788 (0%) | 0% | 79.5 | 144,224 | Common Stock |
| Scott D. Coward | Chief Administrative Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 78.33 per share. | 14 Feb 2022 | 3,972 | 5,601 (0%) | 0% | 78.3 | 311,127 | Common Stock |
| Scott D. Coward | Chief Administrative Officer | Grant, award, or other acquisition of securities at price $ 64.74 per share. | 14 Feb 2022 | 328 | 1,629 (0%) | 0% | 64.7 | 21,235 | Common Stock |
| Jeffrey T. Elliott | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 78.33 per share. | 14 Feb 2022 | 3,972 | 8,150 (0%) | 0% | 78.3 | 311,127 | Common Stock |
| Jeffrey T. Elliott | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 79.55 per share. | 14 Feb 2022 | 1,839 | 6,311 (0%) | 0% | 79.5 | 146,292 | Common Stock |
| Jeffrey T. Elliott | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 3,972 | 7,944 | - | - | Restricted Stock Units | |
| Sarah Condella | SVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 2,030 | 4,061 | - | - | Restricted Stock Units | |
| Sarah Condella | SVP, Human Resources | Sale of securities on an exchange or to another person at price $ 79.55 per share. | 14 Feb 2022 | 938 | 81,574 (0%) | 0% | 79.6 | 74,618 | Common Stock |
| Sarah Condella | SVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 78.33 per share. | 14 Feb 2022 | 2,030 | 82,512 (0%) | 0% | 78.3 | 159,010 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 6,407 | 670,787 (0%) | 0% | 0 | Common Stock | |
| Jeffrey T. Elliott | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 3,972 | 4,178 (0%) | 0% | 0 | Common Stock | |
| Kevin T. Conroy | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 93.88 per share. | 01 Nov 2021 | 16,922 | 664,380 (0%) | 0% | 93.9 | 1,588,637 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 93.64 per share. | 01 Oct 2021 | 17,078 | 681,302 (0%) | 0% | 93.6 | 1,599,184 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 104.42 per share. | 01 Sep 2021 | 18,978 | 698,380 (0%) | 0% | 104.4 | 1,981,683 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 107.50 per share. | 02 Aug 2021 | 19,970 | 717,358 (0%) | 0% | 107.5 | 2,146,775 | Common Stock |
| Katherine S. Zanotti | Director | Sale of securities on an exchange or to another person at price $ 111.11 per share. | 30 Jul 2021 | 1,381 | 34,741 (0%) | 0% | 111.1 | 153,439 | Common Stock |
| James E. Doyle | Director | Sale of securities on an exchange or to another person at price $ 111.17 per share. | 30 Jul 2021 | 2,640 | 29,830 (0%) | 0% | 111.2 | 293,489 | Common Stock |
| James E. Doyle | Director | Sale of securities on an exchange or to another person at price $ 111.17 per share. | 30 Jul 2021 | 2,640 | 29,830 (0%) | 0% | 111.2 | 293,489 | Common Stock |
| Jeffrey T. Elliott | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 114.41 per share. | 29 Jul 2021 | 1,248 | 206 (0%) | 0% | 114.4 | 142,779 | Common Stock |
| Jeffrey T. Elliott | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 113.35 per share. | 29 Jul 2021 | 1,899 | 1,454 (0%) | 0% | 113.4 | 215,258 | Common Stock |
| Jeffrey T. Elliott | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 112.39 per share. | 29 Jul 2021 | 8,675 | 3,353 (0%) | 0% | 112.4 | 974,962 | Common Stock |
| Jeffrey T. Elliott | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 111.58 per share. | 29 Jul 2021 | 13,853 | 12,028 (0%) | 0% | 111.6 | 1,545,707 | Common Stock |
| Jeffrey T. Elliott | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 110.64 per share. | 29 Jul 2021 | 7,818 | 25,881 (0%) | 0% | 110.6 | 864,959 | Common Stock |
| Jeffrey T. Elliott | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 109.58 per share. | 29 Jul 2021 | 2,602 | 33,699 (0%) | 0% | 109.6 | 285,117 | Common Stock |
| Jeffrey T. Elliott | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 108.54 per share. | 29 Jul 2021 | 1,066 | 36,301 (0%) | 0% | 108.5 | 115,699 | Common Stock |
| Jeffrey T. Elliott | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 107.54 per share. | 29 Jul 2021 | 1,200 | 37,367 (0%) | 0% | 107.5 | 129,049 | Common Stock |
| Jeffrey T. Elliott | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 103.22 per share. | 29 Jul 2021 | 206 | 38,567 (0%) | 0% | 103.2 | 21,263 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 123.43 per share. | 01 Jul 2021 | 7,784 | 737,328 (0%) | 0% | 123.4 | 960,779 | Common Stock |
| Katherine S. Zanotti | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 2,011 | 36,122 (0%) | 0% | 0 | Common Stock | |
| Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 2,567 | 5,496 (0%) | 0% | 0 | Common Stock | |
| Freda C. Lewis-Hall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 2,011 | 10,483 (0%) | 0% | 0 | Common Stock | |
| Daniel Joseph Levangie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 2,675 | 17,691 (0%) | 0% | 0 | Common Stock | |
| James E. Doyle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 2,011 | 32,470 (0%) | 0% | 0 | Common Stock | |
| Shacey Petrovic | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 2,011 | 8,357 (0%) | 0% | 0 | Common Stock | |
| Kathleen Sebelius | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 2,699 | 13,877 (0%) | 0% | 0 | Common Stock | |
| Pierre Jacquet | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 2,599 | 11,753 (0%) | 0% | 0 | Common Stock | |
| Thomas D. Carey | Director | Sale of securities on an exchange or to another person at price $ 108.11 per share. | 02 Jun 2021 | 17,000 | 5,292 (0%) | 0% | 108.1 | 1,837,870 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 111.00 per share. | 01 Jun 2021 | 12,384 | 745,112 (0%) | 0% | 111 | 1,374,624 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 64.74 per share. | 03 May 2021 | 328 | 776,736 (0%) | 0% | 64.7 | 21,235 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 131.09 per share. | 03 May 2021 | 19,240 | 757,496 (0%) | 0% | 131.1 | 2,522,172 | Common Stock |
| Sarah Condella | SVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2021 | 1,950 | 10,900 | - | - | Stock Option (right to buy) | |
| Sarah Condella | SVP, Human Resources | Grant, award, or other acquisition of securities at price $ 64.74 per share. | 30 Apr 2021 | 328 | 74,380 (0%) | 0% | 64.7 | 21,235 | Common Stock |
| Sarah Condella | SVP, Human Resources | Sale of securities on an exchange or to another person at price $ 120.00 per share. | 30 Apr 2021 | 3,500 | 70,880 (0%) | 0% | 120 | 420,000 | Common Stock |
| Sarah Condella | SVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.03 per share. | 30 Apr 2021 | 1,950 | 72,830 (0%) | 0% | 5.0 | 9,809 | Common Stock |
| Sarah Condella | SVP, Human Resources | Sale of securities on an exchange or to another person at price $ 120.00 per share. | 30 Apr 2021 | 1,950 | 70,880 (0%) | 0% | 120 | 234,000 | Common Stock |
| Kevin T. Conroy | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 132.30 per share. | 01 Apr 2021 | 22,755 | 776,408 (0%) | 0% | 132.3 | 3,010,487 | Common Stock |
| Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2021 | 2,929 | 2,929 (0%) | 0% | 0 | Common Stock | |
| Graham Lidgard | Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.68 per share. | 11 Mar 2021 | 34,891 | 73,258 (0%) | 0% | 21.7 | 756,437 | Common Stock |
| Graham Lidgard | Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2021 | 8,350 | 4,175 | - | - | Stock Option (right to buy) | |
| Graham Lidgard | Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2021 | 34,891 | 0 | - | - | Stock Option (right to buy) | |
| Graham Lidgard | Chief Science Officer | Sale of securities on an exchange or to another person at price $ 130.00 per share. | 11 Mar 2021 | 43,241 | 38,367 (0%) | 0% | 130 | 5,621,330 | Common Stock |
| Graham Lidgard | Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 44.37 per share. | 11 Mar 2021 | 8,350 | 81,608 (0%) | 0% | 44.4 | 370,490 | Common Stock |
| Graham Lidgard | Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2021 | 4,612 | 34,891 | - | - | Stock Option (right to buy) | |
| Graham Lidgard | Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.68 per share. | 08 Mar 2021 | 4,612 | 38,367 (0%) | 0% | 21.7 | 99,988 | Common Stock |
| Graham Lidgard | Chief Science Officer | Sale of securities on an exchange or to another person at price $ 121.33 per share. | 05 Mar 2021 | 11,735 | 33,755 (0%) | 0% | 121.3 | 1,423,808 | Common Stock |
| Scott D. Coward | Chief Administrative Officer | Sale of securities on an exchange or to another person at price $ 135.02 per share. | 03 Mar 2021 | 2,664 | 1,301 (0%) | 0% | 135.0 | 359,693 | Common Stock |
| Jeffrey T. Elliott | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 135.02 per share. | 03 Mar 2021 | 2,632 | 38,361 (0%) | 0% | 135.0 | 355,373 | Common Stock |
| Graham Lidgard | Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 5,025 | 48,014 (0%) | 0% | 0 | Common Stock | |
| Graham Lidgard | Chief Science Officer | Sale of securities on an exchange or to another person at price $ 138.42 per share. | 01 Mar 2021 | 2,524 | 45,490 (0%) | 0% | 138.4 | 349,372 | Common Stock |